Experimental pill for lung cancer with EGFR or HER2 changes
Part of Cancer, Lungs & breathing clinical trials.
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lung cancer must be advanced (spread to nearby tissues or other parts of the body) and have a change (mutation) in the EGFR or HER2 gene.
- You need to have at least one tumor outside the brain that can be measured on a scan.
- You should be able to take care of yourself (able to do daily activities without major help).
- You must be expected to live at least 3 more months.
- Your health must be generally good, with adequate blood counts and kidney/liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
This trial compares a new targeted therapy pill, HS-10504, with standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. The trial aims to see if the new pill works better than chemotherapy after previous EGFR-targeted treatment has stopped working.
This trial tests a new targeted pill (andamertinib) with or without standard chemotherapy, compared to chemotherapy alone, for people with a rare type of EGFR-mutated lung cancer that has not been treated before. It aims to find which approach works better against the cancer.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This Phase 1/2 study tests a new oral (tablet) cancer medicine called BPI-361175 in people with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. It aims to see how the drug should be dosed and whether it can help shrink or control tumors when earlier standard treatments no longer worked.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.